Rein Therapeutics, Inc. RNTX
We are a clinical stage biopharmaceutical company focused on developing novel therapies for the treatment of orphan pulmonary and fibrosis indications with no approved or limited effective treatments. We currently have two product candidates in clinical development, LTI-03 and LTI-01, however, due to insufficient funding we have paused development of LTI‑01 for an undetermined period of time and are prioritizing LTI‑03. Our pipeline includes:
•LTI-03, a peptide, for which we conducted a Phase 1b dose-ranging, placebo-controlled safety, tolerability, and pharmacodynamic biomarker activity trial in development for the treatment of Idiopathic Pulmonary Fibrosis, or IPF, that has demonstrated the ability to protect healthy lung epithelial cells and reduce pro-fibrotic signaling;
Valuation FY2025 figures against the last close
Annual financial statements
Income statement
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| R&D | $11.0M | $14.2M | $4.0M | $18.0M | $17.0M | $11.2M | $17.7M | $18.4M | $14.2M | $10.3M |
| SG&A | $10.9M | $13.9M | $11.4M | $9.7M | $9.6M | $9.3M | $12.3M | $13.5M | $8.8M | $7.9M |
| Total operating expenses | $50.6M | $65.1M | $16.3M | $27.6M | $26.6M | $20.5M | $30.0M | $31.9M | $23.0M | $18.2M |
| Operating income | -$50.6M | -$65.1M | -$16.3M | -$27.6M | -$26.6M | -$20.5M | -$30.0M | -$31.9M | -$23.0M | -$18.2M |
| Pre-tax income | -$49.2M | -$61.4M | -$15.7M | -$27.3M | -$26.2M | -$27.3M | -$29.4M | -$31.5M | -$22.6M | -$18.1M |
| Income tax | $712.0K | $1.5M | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Net income | -$49.9M | -$62.9M | -$15.7M | -$27.3M | -$26.2M | -$27.3M | -$29.4M | -$31.5M | -$22.6M | -$18.1M |
| EPS, basic | -1.96 | -3.51 | -3.42 | -6.02 | -5.89 | — | — | — | — | — |
| EPS, diluted | -1.96 | -3.51 | -3.42 | -6.02 | -5.89 | -0.61 | -1.20 | -2.14 | -3.04 | -42.35 |
| Shares, diluted (wtd. avg.) | $25.4M | $17.9M | $4.6M | $4.5M | $4.4M | — | — | — | — | — |
Balance sheet
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | $3.2M | $12.9M | $17.3M | $5.2M | $3.6M | $7.0M | $5.3M | $10.6M | $11.9M | $20.7M |
| Short-term investments | — | — | — | $16.0M | $42.3M | $6.8M | $13.0M | $10.1M | $38.9M | $0 |
| Total current assets | $4.3M | $13.7M | $18.3M | $21.9M | $48.2M | $16.3M | $19.6M | $21.8M | $51.8M | $21.1M |
| Property, plant and equipment | $0 | $1.0K | $19.0K | $70.0K | $128.0K | $15.0K | $295.0K | $7.3M | $154.0K | $107.0K |
| Goodwill | $6.3M | $6.3M | $6.3M | — | — | — | — | — | — | — |
| Other intangibles | $13.5M | $42.2M | $79.2M | — | — | — | — | — | — | — |
| Total assets | $24.2M | $62.2M | $106.0M | $22.0M | $48.5M | $16.3M | $26.5M | $30.3M | $52.7M | $22.0M |
| Accounts payable | $4.0M | $911.0K | $1.2M | $1.7M | $1.2M | $1.6M | $1.5M | $1.7M | $1.6M | $2.0M |
| Total current liabilities | $6.2M | $5.7M | $4.4M | $3.4M | $4.5M | $4.0M | $5.8M | $5.4M | $4.9M | $4.1M |
| Total liabilities | $7.2M | $7.8M | $7.7M | $3.4M | $4.6M | $4.2M | $10.4M | $10.7M | $4.9M | $4.1M |
| Retained earnings | -$401.3M | -$351.4M | -$288.5M | -$272.8M | -$245.5M | -$219.3M | -$198.1M | -$168.5M | -$136.9M | -$114.3M |
| Total equity | $16.9M | $54.4M | $98.3M | $18.6M | $43.9M | $12.2M | $16.0M | $19.6M | $47.8M | -$111.8M |
Cash flow
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$19.4M | -$22.3M | -$19.8M | -$24.9M | -$23.8M | -$20.5M | -$26.5M | -$27.9M | -$20.5M | -$15.0M |
| Depreciation and amortisation | $1.0K | $63.0K | $119.0K | $169.0K | $121.0K | $163.0K | $155.0K | $218.0K | $129.0K | $232.0K |
| Stock-based compensation | $2.2M | $1.1M | $1.2M | $2.1M | $2.3M | $1.9M | $2.1M | $3.3M | $1.7M | $688.0K |
| Capital expenditure | — | — | — | — | $157.0K | $5.0K | $151.0K | $4.4M | $142.0K | — |
| Investing cash flow | — | $0 | $16.2M | $26.5M | -$35.9M | $6.4M | -$2.8M | $24.7M | -$38.9M | -$25.0K |
| Financing cash flow | $9.8M | $17.8M | $15.8M | — | $55.7M | $15.8M | $24.0M | $2.5M | $50.6M | $32.0M |
Figures as tagged in each year's own filing, in US dollars. A year restated by a later filing shows the restated figure. Capital expenditure, dividends and buybacks are cash out, shown positive. A line the filer does not report is not listed. Latest from accession 0001193125-26-260809.
Others in SIC 2834
| Ticker | Company | Market cap | P/E | Revenue growth |
|---|---|---|---|---|
| AKTX | Akari Therapeutics Plc | $1.79T | — | — |
| LLY | ELI LILLY & Co | $1.08T | 50.1x | 44.7% |
| JNJ | JOHNSON & JOHNSON | $663.28B | 25.0x | 6.0% |
| ONC | BeOne Medicines Ltd. | $529.55B | 1,885.6x | 40.2% |
| ABBV | AbbVie Inc. | $453.19B | 108.7x | 8.6% |
| MRK | Merck & Co., Inc. | $370.89B | 20.6x | 1.3% |
| ABT | ABBOTT LABORATORIES | $188.69B | 29.1x | 5.7% |
| PFE | PFIZER INC | $162.16B | 20.9x | -1.6% |